Abstract
Autologous peripheral blood stem celt transplantation (auto-PBSCT) has been increasingly used in the treatment of malignant disease, and has begun to replace autologous bone marrow transplantation (autoBMT) because of rapid engraftment and low transplant-related mortality. Some clinical studies have demonstrated the safety and efficacy of high-dose chemotherapy followed by auto-PBSCT for the treatment of acute myelogenous leukemia, malignant lymphoma, multiple myeloma, and solid tumor such as breast cancer. Recently, allogeneic PBSCT (allo-PBSCT) s being evaluated as an alternative to alloBMT. Recent studies suggest that allo-PBSCT results in more rapid engraftment without an apparent increase in acute graft-versus-host disease (aGVHD) as compared to bone marrow, but further studies will be required to assess its efficacy.
Original language | English |
---|---|
Pages (from-to) | 360-369 |
Number of pages | 10 |
Journal | Biotherapy |
Volume | 12 |
Issue number | 3 |
Publication status | Published - Jan 1 1998 |
All Science Journal Classification (ASJC) codes
- Oncology
- Cancer Research